Form 4: Atossa Therapeutics CEO Steven Quay Acquires Stock Options
SEC Form 4 Filing
Atossa Therapeutics' CEO, Steven Quay, was granted stock options to purchase 1,366,062 shares of common stock.
Summary
- Steven C. Quay, CEO of Atossa Therapeutics, was granted stock options on May 15, 2025.
- The options allow him to purchase 1,366,062 shares of Atossa Therapeutics common stock at an exercise price of $0.99 per share.
- The options vest quarterly over 24 months, contingent upon Quay's continued service to the company.
- The options expire on May 15, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the CEO's ability to drive company growth. The vesting schedule promotes long-term commitment.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The size and terms of the grant are typical for a company of Atossa's size and stage of development.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also use stock options to incentivize their executives.
- The vesting schedule of 24 months is fairly standard, aligning with typical performance evaluation cycles.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the CEO's interests with theirs.
- Employees may see it as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of the stock option grant and the earliest transaction date. |
| 05/15/2025 | Start date for the quarterly vesting of the options over 24 months. |
| 05/16/2025 | Date of the Form 4 filing. |
| 05/15/2035 | Expiration date of the stock options. |
Keywords
Atossa Therapeutics, Steven Quay, stock options, Form 4, insider trading, executive compensation, ATOS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.